This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Cancer; other and unspecified primary
  • /
  • Update on the role of trabectedin in the treatment...

Update on the role of trabectedin in the treatment of intractable soft tissue sarcomas.

Read time: 1 mins
Published:23rd Feb 2017
Author: Recine F, Bongiovanni A, Riva N, Fausti V, De Vita A, Mercatali L et al.
Availability: Free full text
Ref.:Onco Targets Ther. 2017;10:1155-1164.

Soft tissue sarcomas (STS) represent a variety of tumors of mesenchymal origin, accounting for about 1% of all adult cancers. This group of tumors comprises over 60 different histotypes with different biology showing different sensitivity to therapeutic agents. For decades, the standard first-line systemic treatment of metastatic STS has comprised anthracycline based-chemotherapy. Second-line therapy options include agents such as ifosfamide, gemcitabine, and pazopanib, but the optimal sequential therapy for the management of metastatic disease has yet to be defined. Trabectedin is one of the new molecules approved for patients in progression after first-line chemotherapy with anthracyclines or for those unfit for these agents. The compound is characterized by multiple potential mechanisms of action combining cytotoxic, targeted, and immunological effects. This article takes an in-depth look at the role of trabectedin in the management of metastatic STS, including L-sarcoma and non-L-sarcoma.


Read abstract on library site

Access full article